Haemostatic changes in children with cyanotic and acyanotic congenital heart disease

M Goel1, D K Shome, Z N Singh

  • 1Department of Paediatrics, Maulana Azad Medical College and GB Pant Hospital, New Delhi.

Indian Heart Journal
|March 21, 2001
PubMed

Insights

Children with cyanotic congenital heart disease show more frequent coagulation abnormalities than acyanotic patients. These findings suggest subclinical disseminated intravascular coagulation and impaired clotting factor synthesis or platelet aggregation.

Area of Science:

  • Pediatric Cardiology
  • Hematology
  • Coagulation Science

Background:

  • Congenital heart disease (CHD) can affect hemostasis.
  • Distinguishing coagulation profiles in cyanotic versus acyanotic CHD is crucial for patient management.

Purpose of the Study:

  • To screen children with CHD for coagulation abnormalities.
  • To compare coagulation systems in cyanotic and acyanotic CHD patient groups.

Main Methods:

  • Comprehensive coagulation screening including CBC, PT, aPTT, fibrinogen, D-dimer, factors VII & VIII, and antithrombin III.
  • Echocardiographically confirmed diagnosis in 25 cyanotic and 25 acyanotic children (<12 years) and age-matched controls.
  • Analysis of red cell indices, bleeding time, and peripheral smear.

Main Results:

  • Isolated laboratory abnormalities occurred with equal frequency (28%) in both acyanotic and cyanotic groups.
  • Multiple coexisting coagulation abnormalities were significantly more common in cyanotic children (16/25 vs. 5/25).
  • Thrombocytopenia and high hematocrit showed a significant association in cyanotic patients.

Conclusions:

  • Laboratory hemostasis abnormalities are more prevalent in cyanotic CHD.
  • Patterns suggest subclinical disseminated intravascular coagulation, reduced clotting factor synthesis, and/or platelet aggregation issues.
  • These findings highlight the need for careful coagulation monitoring in pediatric CHD, especially cyanotic forms.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...